Carogen Corporation

Hamden, CT · Biotech · Private

RNA replicon-based viral vector (VLV) platform for nucleic acid delivery, engineered to carry therapeutic payloads including shRNA targeting PD-L1 for immune checkpoint modulation in viral infection

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · carogencorp.com

Sector: Biotech
Headquarters: Hamden, CT
Total capital: $6M

Federal grants: $6M; 8 awards · 2018–2023; Rank in peer group#112 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 8 pending · first 2026; Rank in peer group#186 of 514

Capital timeline

Latest events

Aug 2023Federal grantHealth and Human S · Phase I · PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine$264K
Apr 2023Federal grantHealth and Human S · Phase II · Gmp Manufacture Of Clinical Grade Therapeutic Vaccine For The Treatment Of Patients With Chronic Hbv$1.1M
Apr 2022Federal grantHealth and Human S · Phase II · Gmp Manufacture Of Clinical Grade Therapeutic Vaccine For The Treatment Of Patients With Chronic Hbv$955K
May 2021Federal grantHealth and Human S · Phase II · Gmp Manufacture Of Clinical Grade Therapeutic Vaccine For The Treatment Of Patients With Chronic Hbv$940K
Sep 2020Federal grantHealth and Human S · Phase I · VLVs as platform for nucleic acid-based delivery:Combining therapeutic vaccine with shRNA-mediated PD-L1 blockade for the treatment of chronic hepatitis B virus$300K
Mar 2020Federal grantHealth and Human S · Phase II · Developing Multi-antigen Vaccine For The Treatment Of Chronic Hbv$768K
Apr 2019Federal grantHealth and Human S · Phase II · Developing Multi-antigen Vaccine For The Treatment Of Chronic Hbv$1.4M

Show 1 earlier federal award

Jun 2018Federal grantHealth and Human S · Phase I · Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#112 · top 22%
Granted patents#186 · top 36%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 9

Mar 17, 2026GrantedCompositions And Methods Of Use Of Oncolytic Virus Like VesiclesUSPTOUS 12,577,585
Dec 5, 2024PendingVersatile Virus-like-vesicles (vlv) Platform For Infectious Diseases And Cancer Immunotherapy ApplicationsUSPTOApplication 18802462
Oct 10, 2024PendingMulti-antigen Therapeutic Vaccines To Treat Or Prevent Chronic Hepatitis B Virus InfectionUSPTOApplication 18755876

Show all 9 patent records

Compositions And Methods Of Use Of Oncolytic Virus Like VesiclesMar 17, 2026 · US 12,577,585Granted
Versatile Virus-like-vesicles (vlv) Platform For Infectious Diseases And Cancer Immunotherapy ApplicationsDec 5, 2024 · Application 18802462Pending
Multi-antigen Therapeutic Vaccines To Treat Or Prevent Chronic Hepatitis B Virus InfectionOct 10, 2024 · Application 18755876Pending
Multi-antigen Therapeutic Vaccines To Treat Or Prevent Chronic Hepatitis B Virus InfectionApplication PCTUS2023060237Pending
Versatile Virus-like-vesicles (vlv) Platform For Infectious Diseases And Cancer Immunotherapy ApplicationsApplication PCTUS2023062986Pending
Rational Design Of Multi-antigen Therapeutic Vaccines To Treat Or Prevent Chronic Hepatitis B Virus InfectionApplication 63308103Pending
Rational Design Of Multi-antigen Therapeutic Vaccines To Treat Or Prevent Chronic Hepatitis B Virus InfectionApplication 63297728Pending
Compositions And Methods Of Use Of Oncolytic Virus Like VesiclesApplication PCTUS2021012834Pending
Versatile Virus-like-vesicles (vlv) Platform For Infectious Diseases And Cancer Immunotherapy ApplicationsApplication 63312816Pending

Ampersand BiomedicinesSimilar federal contract value in Biotech · null in contracts
EXBAQ LLCSimilar federal contract value in Biotech · null in contracts
General Payment Systems, Inc.Similar federal contract value in Biotech · null in contracts
ALKEUS PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
IMMUNIC, INC.Similar federal contract value in Biotech · null in contracts
IRONWOOD PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.